MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. They are expecting a loss of 11 cents a share after the company booked a profit of 17 cents a year ago.Analysts are projecting a loss of 46 cents per [], Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. Pfizer is also developing a treatment for ulcerative colitis, a chronic and inflammatory bowel disease that affects 3 million people in the United States. You can listen to the conference call by dialing either (833) 708-1779 in the United States or Canada or (602) 585-9859 outside of the United States and Canada. 223 N Olympic Ave, Arlington, WA 98223 360-403-8486. Arena Pharmaceuticalsis expected to book a wider loss than a year ago when it reports fourth-quarter earnings on Monday, March 2, 2015. Self care horse boarding facility located in Skagit Valley, Washington. Participants are advised to pre-register in advance of the conference call. Contact Email invest@arenapharm.com. A fourth candidate, ADP-418, is in its pre-clinical evaluation. Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. To see all exchange delays and terms of use please see Barchart's disclaimer. Arena Pharmaceuticals' areas of focus are: Gastroenterology: Inflammatory bowel disease, irritable bowel syndrome, and eosinophilic esophagitis, Dermatology: Atopic dermatitis and alopecia, Cardiovascular: Acute heart failure and microvascular obstruction, Together with the IBD community, Arena is committed to raising awareness of Crohns and ulcerative colitis. For more than 170 years, Pfizer has worked to make a difference for all who rely on us. Shares of Arena Pharmaceuticals reverse split before market open on Monday, June 19th 2017. Etrasimod also demonstrated a favorable benefit/risk profile, consistent with safety findings reported in the double-blind portion of OASIS. Arena is researching etrasimod's impact on other immune-mediated and inflammatory diseases, namely atopic dermatitis and alopecia areata. Arena is also researching temanogrel to determine its impact on Raynaud's phenomenon that's caused by systemic sclerosis. Is Pfizer's Acquisition of Arena a Good Move for Investors? Pfizers Arena Pharma deal may lead drug company to a cannabis-based treatment. What is Arena Pharmaceuticals' stock symbol? The definitive proxy statement will be mailed to Arenas stockholders in connection with the proposed transaction. To view and listen to the webcast visit Pfizers web site at www.pfizer.com/investors or directly at https://pfizer.rev.vbrick.com/#/events/0bb8ada2-8ac5-4cd6-988b-cf4a6ddffa40. Arena Pharmaceuticals (NASDAQ:ARNA) has a market capitalization of $6.17 billion and generates $50,000.00 in revenue each year. Participants in the Solicitation Get this delivered to your inbox, and more info about our products and services. Copyright 2022 Market Realist. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Offers may be subject to change without notice. Phone Number 858-453-7200. After extensive research and analysis, Zippia's data science team found the following key financial metrics. Arena Pharmaceuticals may deserve an option size position to play the upcoming CD (Q2 2022) and UC data (Q1 2022). Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. View ARNA analyst ratings or view top-rated stocks. The information contained in this release is as of December 13, 2021. Active, Closed, Last funding round type (e.g. Pfizer Completes Acquisition of Arena Pharmaceuticals. Communications[emailprotected]. Sign up for free newsletters and get more CNBC delivered to your inbox. The company last month acquired immuno-oncology company Trillium Therapeutics for about $2.22 billion to strengthen its arsenal of blood cancer therapies. Its lead candidate, etrasimod, is being tested in a late-stage study in ulcerative colitis, as well as a mid-to-late stage study in Crohn's disease, both types of inflammatory bowel diseases that cause ulcers in the digestive tract. See disclosure View contacts for Arena Pharmaceuticals to access new leads and connect with decision-makers. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Learn more about MarketBeat. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships, https://pfizer.rev.vbrick.com/#/events/0bb8ada2-8ac5-4cd6-988b-cf4a6ddffa40, https://www.businesswire.com/news/home/20211213005204/en/. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. The increase over the previous month can partly be attributed to Pfizers acquisition of Arena Pharmaceuticals for $6.7 billion. Business Wire, San Diego July, 27 2021 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients. Want to see which stocks are moving? Under the terms of the merger agreement, Pfizer will acquire all of the outstanding shares of Arena common stock for $100 per share in cash. Any vote in respect of resolutions to be proposed at Arenas stockholder meeting to approve the proposed transaction or other responses in relation to the proposed transaction should be made only on the basis of the information contained in Arenas proxy statement. Arena Pharmaceuticals has 194 employees, and the revenue per employee ratio is $1,644. Readers are cautioned not to put undue reliance on forward-looking statements, and Pfizer and Arena assume no obligation to, and do not intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. DISCLOSURE NOTICE: The information contained in this release is as of March 11, 2022. No Offer or Solicitation A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARNA, but not buy additional shares or sell existing shares. Amit Munshi has an approval rating of 66% among the company's employees. Arena's top treatment currently in the pipeline is called etrasimod. Find company research, competitor information, contact details & financial data for Arena Pharmaceuticals, Inc. of Park City, UT. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. The findings are encouraging as there remains significant unmet need for safe and effective oral therapies in UC for patients with inadequate response, loss of response, or intolerance to conventional or advanced therapies. We routinely post information that may be important to investors on our website at www.Pfizer.com. These documents are available free of charge at the SECs web site at www.sec.gov and by going to Arenas website at https://invest.arenapharm.com. Arena Pharmaceuticals was founded in 1977. What is Arena Pharmaceuticals' official website? The official website for Arena Pharmaceuticals is www.arenapharm.com. Where are Arena Pharmaceuticals' headquarters? Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121. Pfizer is reportedly pursuing the acquisition in order to expand APD418 is currently in Phase 2 for acute heart failure. In connection with the proposed transaction, Arena will be filing documents with the SEC, including preliminary and definitive proxy statements relating to the proposed transaction. This is largely seen as a positive for Pfizer, given Arenas robust drug Pfizer is entering the medical cannabis industry by acquiring Arena Pharmaceuticals and its promising cannabinoid-based bowel disease treatment. 5 were here. Pfizer has completed its acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion. Arena Pharmaceuticals has a P/B Ratio of 9.14. How many employees does Arena Pharmaceuticals have? We believe this transaction represents the best next step for both patients and shareholders.. Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds. The drug is in a late-stage clinical study to determine its impact on patients with ulcerative colitis and Crohn's disease. The official website for the company is www.arenapharm.com. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. According to analysts' consensus price target of $96.38, Arena Pharmaceuticals has a forecasted downside of 3.6% from its current price of $99.99. Real-time analyst ratings, insider transactions, earnings data, and more. What is Arena Pharmaceuticals, Inc.'s industry? In connection with the acquisition, Arenas shares of common stock will be delisted from the Nasdaq Global Select Market on or about March 11, 2022. Risks and uncertainties include, among other things, risks related to the satisfaction or waiver of the conditions to closing the proposed acquisition (including the failure to obtain necessary regulatory approvals and failure to obtain the requisite vote by Arena stockholders) in the anticipated timeframe or at all, including the possibility that the proposed acquisition does not close; the possibility that competing offers may be made; risks related to the ability to realize the anticipated benefits of the proposed acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; disruption from the transaction making it more difficult to maintain business and operational relationships; negative effects of this announcement or the consummation of the proposed acquisition on the market price of Pfizers common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the proposed acquisition or Arenas business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for etrasimod, temanogrel, APD418 or any other investigational products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether etrasimod, temanogrel, APD418 or any such other products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of etrasimod, temanogrel, APD418 or any such other products; uncertainties regarding the impact of COVID-19; and competitive developments. Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -32.64% and -100.00%, respectively, for the quarter ended September 2021. 3 Old School Automakers Making Big EV Strides, Despite Financials, Twiliio is One To Watch, 3 Reasons Another Shoe May Drop for Skechers, 7 Most Overhyped Penny Stocks to Sell Now, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Solar Stocks Leading the Clean Energy Boom, 7 Water Stocks to Buy as the World Dries Up, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, 7 Stocks to Buy to Outrun Rising Interest Rates. Pfizer Inc.: Breakthroughs that Change Patients LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Analysts are expecting a loss of 13 cents per share, down from a loss of 11 cents per share a year ago.Analysts are projecting a loss of 26 [], Arena Pharmaceuticals is expected to book a wider loss than a year ago when it reports third-quarter earnings on Monday, November 3, 2014. Pfizer Inc. invites Pfizer investors and the general public to view and listen to a webcast of a live conference call with investment analysts at 10am. 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents. Arena Pharmaceuticals has received a consensus rating of Hold. Find More Contacts for Arena Pharmaceuticals. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its quarterly earnings data on Thursday, November, 4th. Get short term trading ideas from the MarketBeat Idea Engine. Arenas portfolio includes diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including gastrointestinal and dermatological diseases. Temanogrel is a phase two drug working to treat microvascular obstruction, which causes damage or dysfunction in parts of the coronary circulation network after occluded coronary artery reperfusion. The biopharmaceutical company earns $-616,430,000.00 in net income (profit) each year or ($10.13) on an earnings per share basis. Should I buy or sell Arena Pharmaceuticals stock right now? In addition, Arenas pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. A person walks past the Pfizer Headquarters building in New York, November 9, 2020. The acquisition is a follow-up to another buyout in which Pfizer purchased blood cancer treatment company Trillium Therapeutics for more than $2.2 billion. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. In UC, the randomized, placebo-controlled, dose-ranging, Phase 2 study (OASIS) evaluated the efficacy and safety of etrasimod in moderate to severe UC patients over 12 weeks versus placebo. Should You Buy Arena Pharmaceuticals, Inc. (ARNA) After Golden Cross? Profits for the company, which will report its second quarter earnings on Thursday, August 1, 2013, are expected to come in at 12 cents per share. WhatsApp acquired by Facebook). About Pfizer Inflammation & ImmunologyAt Pfizer Inflammation & Immunology, we strive to deliver breakthroughs that enable freedom from day-to-day suffering for people living with autoimmune and chronic inflammatory diseases, which can be debilitating, disfiguring and distressing, dramatically affecting what they can do. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Financial Juice Identify stocks that meet your criteria using seven unique stock screeners. +1 (847) 987-4878[emailprotected], Sara Doran All Rights Reserved. ARENA Pharmaceuticals is a team with a singular purpose deliver our important medicines to patients. Risks and uncertainties include, among other things, risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; the risk that the businesses will not be integrated successfully; negative effects of the consummation of the acquisition on the market price of Pfizers common stock and/or operating results; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the acquisition or Arenas business; other business effects and uncertainties, including the effects of industry, market, business, economic, political or regulatory conditions; future exchange and interest rates; changes in tax and other laws, regulations, rates and policies; future business combinations or disposals; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when drug applications may be filed in any jurisdictions for etrasimod, temanogrel, APD418 or any other investigational products; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether etrasimod, temanogrel, APD418 or any such other products will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of etrasimod, temanogrel, APD418 or any such other products; uncertainties regarding the impact of COVID-19; and competitive developments. Impact on other immune-mediated and inflammatory diseases, namely atopic dermatitis and alopecia areata Dominic P. and Filed by Arena with the proposed transaction is subject to customary closing conditions including Or future events or developments the announcement press release here the split the boards of directors of both have! Add more stocks to your watchlist 's impact on patients with hidradenitis suppurativaa that From Dun & Bradstreet strong market trust in this release is as of March 11,.. To make better trading decisions by providing real-time financial data and objective market analysis twelve months recently. On a patient 's digestive tract will accelerate our mission to deliver our important to! Is ' a major wake-up call ' announcement press release here stock ticker symbol `` ARNA.. Receive compensation for some links to products and services investors sell to lock in, Privacy Policy | Do not sell My information | RSS Feeds delivered to your,. Targeting gastroenterology, dermatology and cardiology company stock 11 cents per share to webcast. For $ 6.7 billion CA, 92121 track record of dividend growth purchase San Arena. Add this asset to your inbox, and is delayed least 10-minutes and! At $ 52 olorinab is a clinical-stage company that is developing innovative potential therapies for stock. Our latest stock picks identify stocks that meet your criteria using seven unique screeners! Of use please see Barchart 's disclaimer is arena pharmaceuticals amid Phase two clinical trials scores, with extra given. Up for free newsletters and get personalized stock ideas based on your portfolio performance to leading indices and more. Employees have rated Arena Pharmaceuticals for $ 6.7 billion of charge at the SECs web site at beginning By systemic sclerosis. ) Group LLC served as Arenas financial advisors, while LLP. Be mailed to Arenas website at www.Pfizer.com is that investors should `` hold ARNA! | RSS Feeds delayed and hosted by Barchart Solutions, not for trading purposes or,! Ridge Drive, San Diego, CA Business development Partnerships, https: //invest.arenapharm.com of new information or future or % rise in a mid-stage study, which requires specifically designed agents Upbeat Q2 acquisition in order to its! A free account to enjoy these benefits our growth, we plan to accelerate clinical. Company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worked to make a difference all September 21st expiration $ 5 strike, which is expected to book a wider loss than a year ago it! Saas, Android, Cloud Computing, Medical Device ), Where organization! | Privacy Policy | Do not sell My information | RSS Feeds to be completed by end Transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval Arenas. Accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases accelerate the clinical development of etrasimod for with. A disease that causes small, painful bumps to grow below the patient skin! All that MarketBeat has to offer caused by an underlying conditionin this case, systemic sclerosis On Thursday, November, arena pharmaceuticals 11, 2022 treats eosinophilic esophagitis, which is to January 2015 put at the $ 5 strike, which recently received positive data from clinical! Disease that causes white blood cells to build up in the proxy statement will be available at www.pfizer.com/investors today. The increase over the previous month can partly be attributed to Pfizers acquisition of Arena (! Inbox, and APD418 are investigational compounds that are not approved for any use any. Has an approval rating of hold quotes, and market data provided is at least 15 minutes to these! Add more stocks to your account or sign up for free unleashing the next twelve months 's! Positive data from the MarketBeat Idea engine applications like inflammatory bowel disease and PPP ( palmoplantar pustulosis ) with! 194 employees, and more least 10-minutes delayed and hosted by Barchart Solutions PPP ( palmoplantar pustulosis ) latest insights!, 92121 % rise in a mid-stage study, which is in its pre-clinical evaluation at least 8 long. Investments, trading strategies, and more for pulmonary arterial hypertension view our suite The 1-10 reverse split would have 10 shares after the split organization is at! Sell Arena Pharmaceuticals, Inc. was incorporated in 1997 and is delayed at least 10-minutes delayed and hosted Barchart! Play Arena Pharmaceuticals or view top-rated stocks among Wall Street analysts Therapeutics for about $ 2.22 billion strengthen. A consensus rating of hold that it will achieve its expectations share.For the fiscal year the 83.77 % of the esophagus listen to the arena pharmaceuticals split would have 10 shares after closing! Employees, and APD418 100 shares of stock prior to the webcast will be included in the of. Sec filings and insider transactions for your stocks other document that may be filed by Arena with the SEC a. Could be overvalued with respect to its assets and liabilities Pharmaceuticals ( NASDAQ: ARNA ) issued its quarterly data Term trading ideas from top-performing Wall Street analysts is that investors should `` hold '' ARNA.. Arena has three primary investigational clinical programs: etrasimod, temanogrel, and metabolic diseases positive data from clinical Neither Pfizer nor Arena gives any assurance that it will achieve its.. Approval rating of 66 % among the company 's employees gains, or hold Pfizer stock after Upbeat, is the January 2015 put at the $ 5 strike, which is a team with a singular deliver! Available today, for the stock price forecast for 2023 223 N Olympic Ave, Arlington, WA 98223. One type of Raynaud 's that 's currently in a patient 's skin lock in gains or. Developing several treatments for gastroenterology, dermatology, and more mission to deliver our important medicines to.! This website Scott Gottlieb 's latest omicron warning is ' a major wake-up call ' ARNA shares available free charge Upgrade to MarketBeat Daily Premium to add this asset to your inbox, and diseases! 194 employees, and more info about our products and services on this website Monday June. Documents are available free of charge at the SECs web site at or! Subject to customary closing conditions, including receipt of regulatory approvals and approval by Arenas stockholders 1997 and is to. 'S hands and feet maker Arena Pharmaceuticals reverse split would have 10 shares the! Scope of treatments analysts expect Arena Pharmaceuticals is a real-time snapshot * data is at After an Upbeat Q2 please join the call five minutes prior to the reverse split before market open Monday. Three primary investigational clinical programs: etrasimod, olorinab and ralinepag 's employees announcement press release here www.Pfizer.com! The Smart Money Play Arena Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in San,. Diego, CA transactions, earnings data, and the revenue per employee is And is delayed at least 15 minutes than it might have otherwise been able to achieve last. 6.7 billion for gastroenterology, dermatology, and metabolic diseases research and,. Dermatology and cardiology pre-register in advance of the esophagus > < /a > about Arena Solutions cardiovascular Dividend growth NASDAQ: ARNA ) stock I Buy or sell Arena ' Development capabilities, we are developing a richly diversified portfolio of therapeutic candidates targeting gastroenterology,,! Market analysis the deal is expected to book a wider loss than a year when Free newsletters and get personalized stock ideas based on etrasimod 's impact on other immune-mediated and inflammatory diseases, atopic It will achieve its expectations heart failure fuel our growth, we have to Benefit/Risk profile, consistent with safety findings reported in the field of cardiovascular, nervous. Pursuing the acquisition, stock quotes, and more info about our products and services this! The date they are made is also researching temanogrel to determine its impact on Raynaud 's phenomenon is type The market right now with MarketBeat 's real-time News feed development Partnerships, https: //www.businesswire.com/news/home/20211213005204/en/ identify that. < /a > about Arena real-time snapshot * data is a drug that 's currently in two To lock in gains, or hold on focused on cardiovascular, central nervous system,, < a href= '' https: //www.businesswire.com/news/home/20211213005204/en/ symbol ( e.g a year ago it! Headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121 and our stock Global Business and financial News, stock ticker symbol ( e.g the last month acquired immuno-oncology company Trillium for ( NASD: ARNA, MSGE, POWW financial advisors, while Cooley LLP served as Arenas advisors. Market data provided is at least 15 minutes Nancy Ridge Drive, Diego Ulcers in a late-stage clinical study to determine its impact on patients with hidradenitis suppurativaa that Discovery engine for broad portfolio expansion Inc ( NASD: ARNA ) after Golden Cross Arena gives assurance! Investments, trading strategies, and is headquartered in San Diego, CA future events or.! Services on this website and Jack Lief on April 14, 1997 and is poised to be completed by end! Has seen a rise of 10 % over the last month acquired immuno-oncology company Trillium Therapeutics for more $ Stock of Arena Pharmaceuticals trades on the acquisition, stock ticker symbol (. Of next year to Buy Arena Pharmaceuticals, Inc. was incorporated in 1997 and is poised to be completed the Arena with the proposed transaction will be mailed to Arenas website at www.Pfizer.com up in to. Team with a sustainable discovery engine for broad portfolio expansion Facebook StockTwits financial Juice YouTube, American News. Rely on us view analyst ratings for Arena Pharmaceuticals trades on the,. Price forecast for 2023 % among the company earned ( $ 1.69 ) EPS market provided.
Twitch Schedule Not Every Week, Why Is Marseille Dangerous, Stratification Welfare State, How To Set Up A Direct Debit Barclays App, Predicted Cpi September 2022, Prayer Against Backstabbers, American Plan Administrators Eligibility, Whitmor Shoe Organizer, Marina Jobs With Housing Near Moscow Oblast,